Loading...
Market
What will be Lantheus' revenue growth rate for fiscal year 2026?
3
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
11% to 15% • 25%
More than 15% • 25%
Annual financial reports of Lantheus Holdings Inc.
Story
Lantheus Acquires Life Molecular Imaging for $350 Million, Adding Neuraceq to Alzheimer's Diagnostics
Jan 13, 2025, 06:34 AM
Lantheus Holdings Inc. has agreed to acquire Life Molecular Imaging for an upfront payment of $350 million, with potential additional payments of up to $400 million based on future sales milestones. The acquisition aims to bolster Lantheus' position in the growing Alzheimer's disease radiodiagnostic market by adding Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's disease. The transaction is expected to enhance Lantheus' growth profile and establish a commercial Alzheimer's disease franchise. Life Healthcare Group Holdings, the current owner of Life Molecular Imaging, plans to return the net proceeds from the upfront payment to shareholders within 12 months of the deal's completion, expected in the second half of 2025.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by 10% to 20% • 25%
Remain within ±10% • 25%
Decrease by more than 10% • 25%
No • 50%
Yes • 50%
20.01% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
Between 0% and 10% • 25%
Above 20% • 25%
Between 10% and 20% • 25%
Negative growth • 25%
No • 50%
Yes • 50%
20% to 30% • 25%
10% to 20% • 25%
Above 30% • 25%
Below 10% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
Above 30% • 25%
Growth of 10% or more • 25%
No growth or decline • 25%
Growth less than 5% • 25%
Growth between 5% and 10% • 25%
Growth > 15% • 25%
Growth between 5% and 15% • 25%
Growth between 0% and 5% • 25%
Negative growth • 25%
10% to 15% • 25%
Less than 5% • 25%
More than 15% • 25%
5% to 10% • 25%